CA2971520C - Methods for wound healing - Google Patents

Methods for wound healing Download PDF

Info

Publication number
CA2971520C
CA2971520C CA2971520A CA2971520A CA2971520C CA 2971520 C CA2971520 C CA 2971520C CA 2971520 A CA2971520 A CA 2971520A CA 2971520 A CA2971520 A CA 2971520A CA 2971520 C CA2971520 C CA 2971520C
Authority
CA
Canada
Prior art keywords
bacteria
wound
seq
protein
sequence
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CA2971520A
Other languages
English (en)
French (fr)
Other versions
CA2971520A1 (en
Inventor
Evelina Vagesjo
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ilya Pharma AB
Original Assignee
Ilya Pharma AB
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ilya Pharma AB filed Critical Ilya Pharma AB
Publication of CA2971520A1 publication Critical patent/CA2971520A1/en
Application granted granted Critical
Publication of CA2971520C publication Critical patent/CA2971520C/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/74—Vectors or expression systems specially adapted for prokaryotic hosts other than E. coli, e.g. Lactobacillus, Micromonospora
    • C12N15/746—Vectors or expression systems specially adapted for prokaryotic hosts other than E. coli, e.g. Lactobacillus, Micromonospora for lactic acid bacteria (Streptococcus; Lactococcus; Lactobacillus; Pediococcus; Enterococcus; Leuconostoc; Propionibacterium; Bifidobacterium; Sporolactobacillus)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A61K35/741—Probiotics
    • A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L26/00—Chemical aspects of, or use of materials for, wound dressings or bandages in liquid, gel or powder form
    • A61L26/0057—Ingredients of undetermined constitution or reaction products thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/521—Chemokines
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00—Microorganisms; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/20—Bacteria; Culture media therefor
    • C12N1/205—Bacterial isolates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
    • A61L2300/20—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices containing or releasing organic materials
    • A61L2300/252—Polypeptides, proteins, e.g. glycoproteins, lipoproteins, cytokines
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12R—INDEXING SCHEME ASSOCIATED WITH SUBCLASSES C12C - C12Q, RELATING TO MICROORGANISMS
    • C12R2001/00—Microorganisms ; Processes using microorganisms
    • C12R2001/01—Bacteria or Actinomycetales ; using bacteria or Actinomycetales
    • C12R2001/225—Lactobacillus

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Biophysics (AREA)
  • Mycology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Toxicology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Materials Engineering (AREA)
  • Virology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Dermatology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CA2971520A 2014-12-23 2015-12-23 Methods for wound healing Active CA2971520C (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
SE1451658 2014-12-23
SE1451658-7 2014-12-23
PCT/EP2015/081146 WO2016102660A1 (en) 2014-12-23 2015-12-23 Methods for wound healing

Publications (2)

Publication Number Publication Date
CA2971520A1 CA2971520A1 (en) 2016-06-30
CA2971520C true CA2971520C (en) 2024-04-09

Family

ID=55080095

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2971520A Active CA2971520C (en) 2014-12-23 2015-12-23 Methods for wound healing

Country Status (9)

Country Link
US (3) US10696974B2 (enExample)
EP (2) EP3237622B1 (enExample)
JP (2) JP6581208B2 (enExample)
KR (2) KR102081493B1 (enExample)
CN (2) CN113403244B (enExample)
AU (2) AU2015370982B2 (enExample)
CA (1) CA2971520C (enExample)
ES (2) ES3048233T3 (enExample)
WO (1) WO2016102660A1 (enExample)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3408378B1 (en) 2016-01-25 2022-01-12 NantCell, Inc. Nk cells with altered cxcl12/cxcr4 signaling
BR112019007812A2 (pt) * 2016-10-31 2019-07-16 Kimberly Clark Co métodos para arquivar e de recriar um microbioma.
US20240024388A1 (en) * 2017-02-17 2024-01-25 The University Of British Columbia Probiotic compositions and uses thereof
CN110157733A (zh) * 2018-02-11 2019-08-23 四川大学 重组mIL-22BP载体、脂质体复合物及其制备方法和用途
EP3827102A1 (en) * 2018-07-24 2021-06-02 Biogaia AB Therapeutic methods using bacterial strains which are capable of increasing adenosine levels
US11911424B2 (en) * 2018-07-24 2024-02-27 Biogaia Ab Selection and use of melatonin supporting bacteria to reduce infantile colic
CN109112155A (zh) * 2018-08-02 2019-01-01 南昌大学 乳酸乳球菌mg1363的构建及其在治疗细菌性阴道炎中的应用
CN109517772A (zh) * 2018-10-30 2019-03-26 南昌大学 一种乳酸乳球菌mg1363的构建及其在治疗产妇乳头皲裂中的应用
CN109234298A (zh) * 2018-10-30 2019-01-18 南昌大学 一种卷曲乳杆菌atcc55221的构建及其在治疗产妇乳头皲裂中的应用
JP7045671B2 (ja) * 2018-11-12 2022-04-01 有限会社バイオ研 皮膚塗布用の皮膚創傷治癒促進組成物、その製造方法、及び創傷被覆材
JP7525911B2 (ja) * 2019-06-24 2024-07-31 メンデス・ソシエタ・ア・レスポンサビリタ・リミタータ プロバイオティクスを含む抗菌および再上皮化作用を有する組成物
CN110623792B (zh) * 2019-09-23 2022-05-06 温州医科大学附属第一医院 一种医学敷料及其制备方法
CN114470007B (zh) * 2020-11-13 2024-10-18 葡萄王生技股份有限公司 含乳酸菌发酵产物之皮肤创伤外用组合物及其用途
JPWO2023063314A1 (enExample) 2021-10-11 2023-04-20
WO2023118327A1 (en) 2021-12-22 2023-06-29 Ilya Pharma Ab Live bacteria as excipients for proteins
KR20240131363A (ko) * 2021-12-29 2024-08-30 일리야 팔마 에이비 요법-유도된 장병증의 치료
KR102752056B1 (ko) * 2023-07-12 2025-01-13 전남대학교 산학협력단 락토바실러스 루터리(Lactobacillus reuteri) NCHBL-005 균주를 포함하는 창상 예방 또는 치료, 피부 재생 촉진용 조성물
GB202405882D0 (en) 2024-04-26 2024-06-12 Ilya Pharma Ab Treatment of mdr infections
CN118948906B (zh) * 2024-10-16 2025-02-14 温州医科大学附属第一医院 一种促进创面愈合的乳酸杆菌生物膜衍生物及其制备方法和应用

Family Cites Families (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9521568D0 (en) * 1995-10-20 1995-12-20 Lynxvale Ltd Delivery of biologically active polypeptides
CA2279461A1 (en) * 1997-02-07 1998-08-13 Shionogi & Co., Ltd. Novel mouse cxc chemokine receptor
ES2272311T3 (es) 1999-07-05 2007-05-01 Vlaams Interuniversitair Instituut Voor Biotechnologie Suministro de peptidos trebol.
CA2311201A1 (en) 1999-08-05 2001-02-05 Genset S.A. Ests and encoded human proteins
US7780961B2 (en) 2001-05-03 2010-08-24 Actogenix N.V. Self-containing Lactococcus strain
US7776564B2 (en) * 2004-04-30 2010-08-17 Five Prime Therapeutics, Inc. Stromal cell-derived factor-1 polypeptides, polynucleotides, modulators thereof and methods of use
WO2006018446A2 (en) 2004-08-20 2006-02-23 Actogenix Nv Method to improve lactococcus preservation
JP5049973B2 (ja) 2005-08-30 2012-10-17 アクトジェニックス・エヌブイ 慢性全腸炎の治療のための、抗−ＴＮＦα産生乳酸菌
US20080254014A1 (en) 2005-10-03 2008-10-16 Actogenix N V Use of Recombinant Yeast Strain Producing an Anti-Inflammatory Compound to Treat Colitis
DK2119450T3 (da) 2005-11-29 2013-05-06 Actogenix Nv Induktion af mucosal tolerance over for pankreatisk ø-beta-celle-autoantigener
US8852916B2 (en) 2010-01-22 2014-10-07 The Invention Science Fund I, Llc Compositions and methods for therapeutic delivery with microorganisms
US8682619B2 (en) * 2005-12-14 2014-03-25 The Invention Science Fund I, Llc Device including altered microorganisms, and methods and systems of use
EP3255149A3 (en) 2006-05-02 2018-04-18 Intrexon Actobiotics NV Microbial intestinal delivery of obesity related peptides
CA2672229A1 (en) 2006-12-14 2008-06-19 Actogenix N.V. Delivery of binding molecules to induce immunomodulation
WO2008074331A1 (en) 2006-12-19 2008-06-26 Ferrosan A/S Wound or tissue dressing comprising lactic acid bacteria
RU2009127718A (ru) 2006-12-19 2011-01-27 Ферросан А/С (Dk) Раневой или тканевой перевязочный материал, содержащий молочнокислые бактерии
CN101605900B (zh) 2007-01-12 2014-04-23 阿克图杰尼斯公司 乳球菌启动子和其用途
BRPI0807857A2 (pt) 2007-01-25 2014-05-27 Actogenix Nv Tratamento de doença imune por meio de distribuição através da mucosa de antígenos.
US20110044945A1 (en) * 2007-02-08 2011-02-24 Rappaport Family Institute For Research In The Medical Sciences Agents for the treatment of multiple sclerosis and methods of using same
EP2164512A2 (en) 2007-06-20 2010-03-24 Actogenix N.V. Methods and compositions for treating mucositis
ATE543507T1 (de) 2007-11-07 2012-02-15 Ono Pharmaceutical Co Sdf-1 enthaltende zusammensetzung mit anhaltender freisetzung
AU2008338525B2 (en) 2007-12-14 2015-04-02 Juventas Therapeutics, Inc. Compositions and methods of promoting wound healing
US8367109B2 (en) 2008-04-09 2013-02-05 Brookhaven Science Associates, Llc Microbes encapsulated within crosslinkable polymers
JP2012504116A (ja) 2008-09-29 2012-02-16 アクトジェニックス・エヌブイ 粘膜での微生物のコロニー形成の低減
US20100143305A1 (en) * 2008-12-08 2010-06-10 James Allen Lemke Treatment of hiv and aids using probiotic lactobacillus reuteri
CN102421894A (zh) 2009-04-21 2012-04-18 迈阿密大学 用于促进局部缺血性和糖尿病性创面愈合的组合物、试剂盒和方法
EP2243487A1 (en) 2009-04-23 2010-10-27 Actogenix N.V. Enteric coated formulation
ES2425385T3 (es) 2009-04-30 2013-10-15 Actogenix N.V. Crioprotectores para la liofilización de las bacterias de ácido láctico
US20100310514A1 (en) * 2009-06-04 2010-12-09 Chi Hin Cho Anti-Inflammatory Bacteria
CL2009001506A1 (es) 2009-07-01 2009-09-25 Univ Concepcion Parche o aposito a base de hidrocoloides compuesto por una lamina de gelatina reticulada que comprende cepas viables probioticas productoras de acido lactico de lactobacillus acidophilus dsm 17371, un agente reticulante y un agente plastificante; y proceso para elaborar dicho parche.
CA2772610C (en) 2009-08-28 2018-01-23 The Cleveland Clinic Foundation Sdf-1 delivery for treating ischemic tissue
EP3192873A1 (en) 2009-09-29 2017-07-19 Intrexon Actobiotics NV Lactobacillus and streptococcus promoters and uses thereof
GB2482536B (en) * 2010-08-05 2013-07-24 Hera Pharmaceuticals Inc Expression of antibody or a fragment thereof in lactobacillus
CN101985052B (zh) 2010-08-31 2013-11-06 中国人民解放军第二军医大学 自动捕获内皮祖细胞促进血管化的皮肤替代物及其构建方法
WO2012150269A1 (en) 2011-05-03 2012-11-08 Dupont Nutrition Biosciences Aps Probiotic bacteria for the topical treatment of skin disorders
EP2714912B1 (en) 2011-06-01 2018-05-02 Intrexon Actobiotics NV Polycistronic expression system for bacteria
HUE038830T2 (hu) 2011-09-23 2018-11-28 Intrexon Actobiotics Nv Módosított gram-pozitív baktériumok és alkalmazásaik
CN103917639B (zh) 2011-09-23 2017-09-26 英特瑞克斯顿阿克图比奥帝克斯有限公司 经修饰的革兰氏阳性细菌及其用途
GB201206599D0 (en) * 2012-04-13 2012-05-30 Univ Manchester Probiotic bacteria
AU2014233266A1 (en) 2013-03-15 2015-10-22 Juventas Therapeutics, Inc. The use of SDF-1 to mitigate scar formation
WO2014146202A1 (en) * 2013-03-18 2014-09-25 London Health Sciences Centre Research Inc. Bacteria for the prevention, treatment and diagnosis of breast cancer
EP4091609A1 (en) 2013-04-29 2022-11-23 Medregen, LLC Wound healing via autologous stem cell mobilization
WO2016124239A1 (en) 2015-02-04 2016-08-11 Aurealis Oy Recombinant probiotic bacteria for use in the treatment of a skin dysfunction

Also Published As

Publication number Publication date
KR20170097194A (ko) 2017-08-25
JP2018502600A (ja) 2018-02-01
AU2015370982A1 (en) 2017-07-13
CN113403244B (zh) 2022-08-19
JP7033109B2 (ja) 2022-03-09
KR102081493B1 (ko) 2020-02-26
EP3735979B1 (en) 2025-08-13
CN113403244A (zh) 2021-09-17
EP3735979C0 (en) 2025-08-13
AU2019204290A1 (en) 2019-07-04
US20230093013A1 (en) 2023-03-23
US20180187202A1 (en) 2018-07-05
EP3237622B1 (en) 2021-02-24
US10696974B2 (en) 2020-06-30
WO2016102660A1 (en) 2016-06-30
ES2864373T3 (es) 2021-10-13
US11473091B2 (en) 2022-10-18
CN107208107A8 (zh) 2017-12-26
CN107208107A (zh) 2017-09-26
KR102297619B1 (ko) 2021-09-02
AU2015370982B2 (en) 2019-03-21
JP6581208B2 (ja) 2019-09-25
EP3735979A1 (en) 2020-11-11
JP2020005646A (ja) 2020-01-16
AU2019204290B2 (en) 2021-12-16
US20200299703A1 (en) 2020-09-24
KR20200020994A (ko) 2020-02-26
CA2971520A1 (en) 2016-06-30
EP3237622A1 (en) 2017-11-01
CN107208107B (zh) 2021-07-09
ES3048233T3 (en) 2025-12-09

Similar Documents

Publication Publication Date Title
US20230093013A1 (en) Methods for wound healing
KR102172228B1 (ko) 재조합 프로바이오틱 세균
US12239695B2 (en) Composition comprising thrombin-treated stem cell-derived exosome for treating skin wound
You et al. Wound-healing potential of human umbilical cord blood–derived mesenchymal stromal cells in vitro—a pilot study
Cai et al. Alpha-ketoglutarate supramolecular network accelerates diabetic wound healing through exudates management and neovascularization
Huang et al. Modulation of macrophages by a phillyrin-loaded thermosensitive hydrogel promotes skin wound healing in mice
WO2023118327A1 (en) Live bacteria as excipients for proteins
HK1242736B (en) Methods for wound healing
HK1242736A1 (en) Methods for wound healing
JP2025139528A (ja) 抗菌剤
TW201805022A (zh) 含有血紅素結合蛋白次單元之蛋白質用於製備促進傷口癒合之醫藥的用途
HK1240848B (en) Recombinant probiotic bacteria

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20201211

MPN Maintenance fee for patent paid

Free format text: FEE DESCRIPTION TEXT: MF (PATENT, 9TH ANNIV.) - STANDARD

Year of fee payment: 9

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20241220

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT DETERMINED COMPLIANT

Effective date: 20241220

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20241220

MPN Maintenance fee for patent paid

Free format text: FEE DESCRIPTION TEXT: MF (PATENT, 10TH ANNIV.) - STANDARD

Year of fee payment: 10

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20251216

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20251216